ARTICLE | Clinical News
Bardoxolone methyl: Phase III started
October 17, 2016 7:00 AM UTC
Reata began the double-blind, placebo-controlled, international Phase III CATALYST trial to evaluate oral bardoxolone methyl once daily for 24 weeks plus vasodilator therapy in 130-200 patients with connective tissue disease-associated PAH. Patients will initially receive 5 mg, which will increase to 10 mg at week 4 unless contraindicated. ...